Should Investors Like Bristol-Myers' Buyout of Celgene?
The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual.
via FOX BUSINESS NEWS https://fxn.ws/2Ty5ty5
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon